Previous research has shown that CPT-1A is upregulated in PCa, and inhibiting CPT-1A in combination with enzalutamide showed a synergistic effect by inhibiting AKT and activating INPP5K [69]. The gene discussed is CPT1A; the disease is posterior cortical atrophy.